Why Freeline Therapeutics (FRLN) stock surged 38% today?

January 06, 2022 09:42 AM PST | By Versha Jain
Follow us on Google News:


  • Freeline Therapeutics Holdings plc (NASDAQ: FRLN) stock jumped 38.78% in premarket on Thursday.

  • The healthcare company received FDA clearance for its investigational new drug (IND) application for FLT201.

  • The stock gained over 6% in a week, but it was down about 88% over the past year.

Shares of Freeline Therapeutics Holdings plc (NASDAQ: FRLN) jumped 38.78% to US$2.72 in the premarket on Thursday after it received clearance from the US Food and Drug Administration (FDA) for its investigational new drug application for FLT201.

The trading volume also rose to 38,184,104 compared to its 90-day average of 126,492.

The stock rallied after the UK-based company on Thursday said that it received approval from the FDA for its investigational new drug application for FLT20.

On Wednesday, the stock closed at US$1.96, down 3.45%.

The FLT201 drug is used for treating type 1 Gaucher disease. 

Also Read: Seven hottest IPOs to explore in 2022

According to Freeline's chief medical officer Pamela Foulds, the preclinical proof studies suggest that FLT201 can reach bone marrow and lungs that are addressed insufficiently by the standard-of-care enzyme replacement therapy.

The data shows the FLT201 treatment might have a transformative impact on reducing or eliminating the enzyme or need for substrate replacement therapy, she added. 

Also Read: Five energy stocks that gave over 100% return in a year

Freeline Therapeutics Holdings plc (FRLN) stock rises on FDA clearance

Also Read: Top technology and gaming stocks to explore in 2022

Freeline Therapeutics Financials

Freeline Therapeutics, founded in 2015, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for treating systemic debilitating diseases in patients. 

The FRLN stock has a P/Book ratio of 0.46. Its 90-day beta is 0.49. 

Freeline launched its IPO in August 2020. It currently has 35.81 million outstanding shares and 32.86 million shares in free-floats.

The stock gained over 6% in the past week. Yearly, it was down 88.36%.

Its peers, Beam Therapeutic, fell 10.19% in one month, and Avrobio Incorp fell 40.52% in the same period.

Also Read: The Great Resignation: Will it continue in 2022?

In the nine months ended Sept 30, 2021, the company earned no revenue. It reported operating expenses of US$108 million.

Its net loss was US$105.7 million or US$(2.96) per share diluted. In the year-ago period, its net loss was US$58 million or US$(8.39) per share diluted, with an operating expense of US$70.19 million. 

The company had US$136.38 million in cash and cash equivalents as of Sept 30, 2021, compared to US$229.97 million as of Dec 31, 2020.

Also Read: Stocks that could give FAANG companies a run for money


The Nasdaq Biotechnology Index fell 9.36% in a year and 3.73% over the past month. The healthcare sector has performed well, helped by the pandemic-fuelled demand for various services. Drug approvals are critical for these companies as they spur bottom-line growth.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Top Listed Companies